The narrative around Chinese electric vehicles is undergoing a fundamental shift. Once known primarily for affordability, leading Chinese automakers are now challenging incumbents with rapidly improving quality, technology, and reliability, forcing a global industry recalibration.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
As inflation persists, Baby Boomers are leveraging decades of financial experience to cut costs strategically. We examine the key spending categories they avoid and the generational mindset behind their money choices.
CNBC's Jim Cramer expressed renewed bullishness on Tesla, shifting focus from its electric vehicle business to its ambitions in robotics and autonomous 'Cybercab' technology following the company's latest earnings call.
Despite modest nominal gains, real wages for U.S. workers are failing to keep pace with the cost of living, with a majority reporting financial strain as structural economic shifts and technological efficiencies redirect gains away from paychecks.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
Investment firm Monument Capital Management has completely exited its position in Grand Canyon Education, selling 19,133 shares. The move comes as the education services provider navigates legal challenges and market underperformance.
NVIDIA has significantly revised its once-floated $100 billion investment plan for OpenAI, opting for a more measured commitment. The strategic shift underscores the chipmaker's focus on business discipline and diversifying its partnerships across the booming AI ecosystem, even as it remains central to OpenAI's operations.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
An analysis of the most-held stocks on the Robinhood platform reveals where the retail investing crowd is placing its bets, with two tech giants emerging as particularly compelling long-term investments.
Adobe and Cognizant are expanding their strategic partnership to help major corporations integrate generative AI into content creation and customer experience workflows. The move targets regulated, high-growth industries grappling with soaring demand for personalized content, positioning Adobe's tools as enterprise-ready solutions amid investor scrutiny over its stock performance.
As Amgen prepares to report earnings, analysts are divided on the stock's trajectory. While strategic acquisitions and a solid track record fuel optimism, looming competitive pressures and a key pipeline wait temper expectations.
As Baidu pivots from its search engine roots, its heavy investments in autonomous vehicle technology are beginning to yield operational results, reshaping analyst views and sparking fresh valuation discussions amidst fierce AI competition.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
